CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
ConditionLymphoma, B-Cell
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age15-80
SponsorShanxi Bethune Hospital
About this trial
The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
Eligibility criteria
Qualifiers
Age≥15 years and ≤80years，female and male；
CD30+ lymphocyte malignancies;
CD30 expression >10% by immunohistochemistry；
At least 1 measurable lesion can be measured according to theLugano 2014 evaluation criteria;
Disqualifiers
Lymphoma-associated hemophagic cell syndrome;
Pregnant or lactating women, and women who have a pregnancy plan within six months;
Hepatitis B（HBsAg、HBsAb、HBeAg、HBeAb、HBcAb），Hepatitis C（Anti-HCV），Anti-HIV Ⅰ/Ⅱ and anti-TP positive（Hepatitis B DNA test is negative except）;
Suffered from other malignant tumors, except for for skin basal cell carcinoma, skin squamous cell carcinoma and cervical carcinoma in situ undergoing the radical treatment;
Trial design
Treatments tested in this trial
- chimeric antigen receptor gene modified T cells
Treatment groups
15 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov